BioWorld

Real-world study: Less bleeding with Ekos than Flowtriever in PE

An analysis of real-world data pulled from Truveta’s electronic health records of 30 U.S. health care systems found that patients treated for pulmonary embolism (PE) using Boston Scientific Corp.’s ...
WTNH

Inari Medical Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism Patients

IRVINE, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous ...
Seeking Alpha

Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)

IRVINE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and ...
Medscape

Controversy Surrounds Optimal Treatment for High-Risk Pulmonary Embolism

VIENNA — The optimal course of treatment when managing acute, high-risk pulmonary embolism (PE) remains a contentious topic among respiratory specialists. Systemic thrombolysis, specifically using ...
Nasdaq

Inari's (NARI) Expanding Product Portfolio Offsets Competition

Inari Medical NARI continues to ride on the success of its ClotTriever and FlowTriever products available for treating venous thromboembolism (VTE). The adoption of these products is rising on the ...